Drug Trial Radar · NCT01106014
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
Last checked: Nov 20, 2026Latest source record: Oct 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,156
Actual
Start
Dec 1, 2009
Primary completion
Apr 1, 2014
Study completion Oct 1, 2014
Sponsor
- Lead sponsor
- ActelionJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Apr 19, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The AC-065A302 (GRIPHON) study is an event-driven Phase 3 study to demonstrate the effect of selexipag on time to first morbidity or mortality event in patients with pulmonary arterial hypertension.
Conditions
- Pulmonary Arterial Hypertension
Interventions
SelexipagDrug
Selexipag 200 µg tablets
PlaceboDrug
Placebo tablets matching selexipag
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time From Randomization to the First Morbidity Event or Death (All Causes) up to 7 Days After the Last Study Drug IntakeTime frame: Up to 7 days after end of double-blind treatment (maximum: 4.3 years)
Locations
182 sites in 39 countries. Site status is shown where the registry gives one.
University of South Alabama
Mobile, Alabama
The University of Arizona, Clinical and Translational Science (CATS) Research Center
Tucson, Arizona
University of California San Diego Medical Center (La Jolla)
La Jolla, California
Cedars-Sinai Medical Center
Los Angeles, California
GLVA Healthcare Center
Los Angeles, California
University of California, Davis, UC Davis Medical Center
Sacramento, California
LIU Center for Pulmonary Hypertension
Torrance, California
Lung Health & Sleep Emhancement Center, LLC
Newark, Delaware
Emory University School of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine
Atlanta, Georgia
Georgia Health Sciences University
Augusta, Georgia
Georgia Clinical Research
Austell, Georgia
Clarian North Hospital
Carmel, Indiana
University of Iowa Hospitals & Clinics
Iowa City, Iowa
Kentuckiana Pulmonary Associates
Louisville, Kentucky
LSU Health Science Center - New Orleans
New Orleans, Louisiana
Johns Hopkins University School of Medicine
Baltimore, Maryland
Tufts Medical Center
Boston, Massachusetts
Massachusetts General Hospital - Pulmonary Critical Care Unit
Boston, Massachusetts
Massachusetts General Hospital-Pulmonary Critical Care Unit
Boston, Massachusetts
Boston University School of Medicine / Boston University Medical Center
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
Henry Ford Hospital
Detroit, Michigan
Beaumont Hospital
Troy, Michigan
Washington University School of Medicine
St Louis, Missouri
Newark Beth Isreal Medical Center-Department of Pulmonary Medicine
Newark, New Jersey
Columbia University Medical Center, Pediatric Cardiology
New York, New York
Montefiore Medical Center, Weiler Division
The Bronx, New York
Duke University Medical Center
Durham, North Carolina
The Lindner Clinical Trial Center
Cincinnati, Ohio
University of Cincinnati
Cincinnati, Ohio
University Hospitals Case Medical Center
Cleveland, Ohio
The Ohio State University Medical Center
Columbus, Ohio
Oregon Pulmonary Associates, PC
Portland, Oregon
Central Bucks Specialists
Doylestown, Pennsylvania
Penn Presbyterian Medical Center
Philadelphia, Pennsylvania
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania
Vanderbilt Medical Center
Nashville, Tennessee
UT Southwestern Medical Center at Dallas
Dallas, Texas
Baylor College of Medicine
Houston, Texas
University of Texas-Houston Health Center Department of Pulmonary & Critical Care
Houston, Texas
Showing 40 of 182 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.